In the case of HER2 monoclonal and bispecific antibodies, it has also been described that modulating tumor infiltrating myeloid cells with agents such as dexamethasone [152], IL4 neutralizers [153], or the small molecule receptor tyrosine kinase cabozantinib [154] can enhance bispecific antibody-driven T cell infiltration and anti-tumor response by reshaping the TME in murine models. Here, ERBB2 is linked to neoplasm.